Sie befinden sich hier

Inhalt

Publikationen

Articles, Letters & Editorials

  1. Heiss MM, Babic R, Allgayer H, Gruetzner U, Jauch KW, Loehrs U, Schildberg FW (1993): Tumour-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. Journal of Clinical Oncology, Vol. 13, No. 8, pp. 2084-2093, 1995.
  2. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW:  Individual development and uPA-receptor-expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Medicine, Vol. 1, No.10, pp.1035-1039, 1995.
  3. Heiss MM, Babic R, Allgayer H, Grützner KU, Jauch KW, Löhrs U, Schildberg FW: The Prognostic Impact of the Urokinase-Type Plasminogen Activator System is Associated with Tumour Differentiation in Gastric Cancer. Eur J Surg Onc, Vol. 22, pp.74 - 77, 1996.
  4. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, Mempel W, Beck KG, Schildberg FW, Messmer K: Perisurgical erythropoietin application in anemic colorectal cancer patients: A double-blind randomized study. Surgery, 119: 523 - 527, 1996.
  5. Heiss MM; Kaden AH, Allgayer H, Piltz S, Jauch KW, Schildberg FW: Prognoseverbesserung durch Metastasenresektion beim malignen Melanom (Prognostic influence of metastases resection in malignant melanoma). Akt Chir 31:294-297, 1996
  6. Heiss MM, Allgayer H, Gruetzner KU, Tarabichi A, Mempel W, Jauch KW, Schildberg FW: Evidence for a blood transfusion effect on minimal residual disease in resected cancer patients. Anticancer Research, 17: 2657 - 2662, 1997.
  7. Heiss MM, Fasol-Merten K, Allgayer H, Ströhlein MA, Tarabichi A, Wallner S, Eissner HJ, Jauch KW, Schildberg FW: Influence of autologous versus allogeneic blood transfusion on NK cell and LAK cell activities in cancer surgery. Vox Sanguinis 73: 237 - 245, 1997.
  8. Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Ströhlein MA, Tarabichi A, Faist E, Jauch KW, Schildberg FW: Modulation of immune response by blood transfusion: Evidence for a differential effect of allogeneic or autologous blood in colorectal cancer surgery. Shock 8:402-408, 1997
  9. Allgayer H, Heiss MM, Riesenberg R, Babic R, Jauch KW, Schildberg FW: Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA-R and CK18: Investigation of sensitivity, specificity and reproducibility of an immunogold/alcaline phosphatase double-staining protocol. J Histochem Cytochem 45(2): 203-212, 1997.
  10. Allgayer H, Heiss MM, Riesenberg R, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW: Urokinase plasminogen activator receptor (uPA-R) -- a potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Research 57: 1394 - 1399, 1997.
  11. Allgayer H, Babic R, Grützner KU, Beyer BCM, Tarabichi A, Schildberg FW, Heiss MM: Immunohistochemical assessment of Cathepsin D in gastric cancer:  Impact on clinical prognosis. Cancer  80: 179 - 187, 1997.
  12. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Loehrs U, Schildberg FW:  Clinical value of an extended biological staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Annals of Surgery 226 (6): 736 - 745, 1997.
  13. Allgayer H, Babic R, Beyer BCM, Grützner KU, Tarabichi A, Schildberg FW, Heiss MM: Prognostic relevance of MMP-2 (72 kD-collagenase IV) in gastric cancer. Oncology 55:152 - 160, 1998.
  14. Allgayer H, Babic R, Grützner KU, Beyer BCM, Tarabichi A, Schildberg FW, Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer:  Analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16: 62 - 73, 1998.
  15. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D: Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signaling molecule. Oncogene 17: 213 – 225, 1998.
  16. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O, Boyd D: Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator-protein-2a-related factor. Journal of Biological Chemistry 274 (8): 4702 – 4714, 1999.
  17. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD: Transcriptional induction of the urokinase-receptor (u-PAR) gene by a constitutively active Src: Requirement of an upstream motif (-152/-135) bound with Sp1. Journal of Biological Chemistry 274 (26), 18428 – 18437, 1999.
  18. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D: Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line downregulates urokinase   receptor expression and plasminogen-dependent proteolysis. British Journal of Cancer 80, 1884, 1999.
  19. Dang J, Boyd D, Wang H, Allgayer H, Doe W, Wang Y: A region between –141 and –61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. European Journal of Biochemistry 264(1):92-9, 1999.
  20. 20. Allgayer H, Babic R, Grützner KU, Tarabichi A, Schildberg FW, Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. The Journal of Clinical Oncology 18(11): 2201 – 2209, 2000.
  21. WangY, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D: Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor.           European Journal of Biochemistry 67(11): 3248-3254, 2000.
  22. Heiss MM, Allgayer H, Funke I, Schildberg, FW: Disseminierte Tumorzellen als Prognosefaktor noch kontrovers. Diskussionsbeitrag zu Izbicki et al., Minimal residuale Tumorerkrankung bei soliden epithelialen Tumoren, Dt. Ärzteblatt 22/2000. Deutsches Ärzteblatt 51/52: 2953 – 2954, 2000. (Letter)
  23. Allgayer H, Heiss, MM: Fazit zu: Die minimal residuale Tumorerkrankung bei soliden Tumoren: Kritische Analyse des aktuellen Status quo. MMW Fortschritte der Medizin 4: 38, 2001. (Letter)
  24. Allgayer H, Heiss, MM: Die minimal residuale Tumorerkrankung bei soliden Tumoren. Fortschr Med Orig 119(1):1-4, 2001.
  25. Lengyel ER, Ried S, Heiss MM, Jäger C, Schmitt M, and Allgayer H: Ras-regulation of urokinase-type plasminogen activator. Methods in Enzymology 333 (G): pp.105-116, 2001.
  26. Allgayer H, Boyd DD, Heiss MM, Curley SA, Gallick GE: Elevated Src kinase activity in primary colorectal cancer is a biological indicator of poor clinical prognosis. Cancer 94: 344 – 351, 2002.
  27. Heiss MM, Simon EH, Beyer BCM, Grützner KU, Tarabichi A, Babic R, Schildberg FW, and Allgayer, H: Minimal residual disease in gastric cancer: First evidence of an independent prognostic relevance of urokinase receptor gene expression by disseminated tumor cells in a large series of patients.       The Journal of Clinical Oncology 20(8):2005-2016, 2002.
  28. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, and Allgayer H: Tumor-specific transcription factor binding to an AP-2/Sp1 promoter element of the urokinase-receptor (u-PAR) promoter in a first large series of resected gastrointestinal cancers. Clinical Cancer Research 9(6): 2267-76, 2003.
  29. Leupold JH, Colburn NH, Yang HS, Boyd DD, Lengyel ER, Jauch KW, und Allgayer H: Erster Hinweis auf eine Rolle des neu beschriebenenen Tumor –Suppressorgens Pdcd4 als Regulator des Invasionsmoleküls Urokinase Rezeptor Langenbecks Arch Surg 2003.
  30. Allgayer H:  Molecular staging of cancer (invited Editorial). J Surg Oncology 82 (4), 217-223, 2003. (Editorial)
  31. Allgayer H: Molekulare Regulation der Invasion von Tumorzellen—Ausgangspunkt für neues Tumor-Staging und eventuell neue Therapieansätze (Eingeladener Letter). Münchner Ärztliche Anzeigen 91(9): 3-4, 2003 (Letter)
  32. Allgayer H: Bericht zur Reise anlässlich der 103. Jahrestagung der Japanischen Gesellschaft für Chirurgie, Juni 2003, Sapporo (Eingeladener Bericht). Mitteilungen der Deutschen Gesellschaft für Chirurgie 4/2003, pp. 431-435 (Letter)
  33. Htun van der Horst E, Leupold JH, Schubbert R, Ullrich A, and Allgayer H: TaqMan® based quantification of invasive cells in the chick embryo metastasis assay. BioTechniques 37 (6): 940- 946, 2004.
  34. Schewe DM, Biller T, Leupold J, Lengyel ER, Schildberg FW, Jauch KW, und Allgayer H: Tumorspezifische Transkriptionsfaktorbindung an den Urokinase-Rezeptor-Promotor. Editorial Rubrik „gastrointestinale Tumore“, Kongresszeitung, Kongress Deutsche Gesellschaft für Chirurgie, 30.4.2004, Kaden-Verlag, S. 14. (Editorial)
  35. Allgayer H:  Institut für molekulare Onkologie(IFOM) und Abteilung Molekulare Genetik am DIBIT-San Raffaele Institut in Milano, Italien—Bericht über einen Forschungsaufenthalt gefördert durch die Sektion Chirurgische Forschung/CAMO. Mitteilungen der Deutschen Gesellschaft für Chirurgie 4/05, pp. 391-392, 2005. (Original Article/Editorial)
  36. Allgayer H: Etablierung und Führung einer Gewebebank. Leitthema, Der Onkologe Suppl 1(11); p. S7-S11, 2005 (Original Article/Editorial)
  37. Schewe DM, Biller T, Maurer G, Leupold JH, Lengyel ER, Post S, and Allgayer H: Combination analysis of AP-1 family members, Sp1 and an AP-2a-related factor binding to different regions of the urokinase receptor (u-PAR) gene in a large series of resected gastrointestinal cancers. Clin Cancer Res 11(24): 8538-8548, 2005
  38. Beyer BCM, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, and Allgayer H: Urokinase-system expression in gastric cancer – Confirmation of prognostic impact in an independent patient series and first evidence for a predictor in preoperative biopsies and intestinal metaplasia. Cancer 1: 106(1): 1026-1035, 2006
  39. Allgayer H, Manegold C, Grobholz R: Establishing a Tumor Tissue Bank—an Interdisciplinary Challenge. Am J Cancer  5(2): 93-98, 2006 (Original Article/Editorial)
  40. Allgayer, H Position Paper: Molecular regulation of an invasion-related molecule – options for tumor staging and clinical strategies. Eur J Cancer 42:7, 811-819, 2006
  41. Wang H, Yan Ch. Asangani I, Allgayer H, Boyd  DD: Identification of an histone H3 acetylated/K9-methylated-bound intragenic enhancer regulatory for constitutive and phorbol ester-inducible urokinase receptor expression. Oncogene 2006, 1-13
  42. Leupold JH, Yang H-S, Colburn NH, Boyd, DD, Lengyel ER, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (uPAR) gene expression via Sp-transcription factors. Oncogene 26(319): 4550-4562, 2007
  43. Leupold JH, Asangani I, Lengyel ER, Post S, Allgayer H: Src-induced uPAR gene expression is also mediated via an AP-1 motif and is associated with increased invasive capacity in vivo. Molecular Cancer Research 5(5):485-496, 2007
  44. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung H-M, Lau-Werner U, Post S, Allgayer H: First analysis of specific transcriptional regulators as predictors of independent prognostic relevance in resected colorectal cancer. Clinical Cancer Research  13(4): 1123-1132, 2007
  45. Mudduluru G, Medved F, Grobholz R, Joste C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition, correlates inversely with pAkt, and is a new and independent prognostic factor in resected colorectal cancer.  Cancer 110:8, 1697-1707, 2007
  46. Schumacher J, Allgayer H: Comparative genomics on the basal mammalian urokinase receptor-promoter and impact for potential in vivo/clinical relevance in cancer. Advances in Gene, Molecular and Cell Therapy 1(1): 1-9, 2007
  47. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, Gretz N. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model.  Br J Cancer. 2007 Nov 19;97(10):1432-40.
  48. Bleier S, Maier P, Allgayer H, Wenz F, Zeller WJ, Frühauf S, Laufs S: Multiple displacement amplification enables large scale clonal analysis after retroviral gene therapy.  J Virology 82(5), 2448-2455, 2008
  49. Asangani IA, Rasheed SAK, Leupold JH, Post S, Allgayer H: NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1(CAPNS1)gene.   Gene 2008, 410(1):197-206.
  50. Asangani IA, Rasheed SAK, Nikolova D, Leupold JH, Colburn NH, Post S, Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis. Oncogene, 3;27(15):2128-36, 2008 (Most cited original article of the Journal Oncogene in 2009)
  51. Mudduluru G, Allgayer H: The human receptor tyrosine kinase Axl gene – promoter characterization and regulation of constitutive expression by Sp1, Sp3, and CpG methylation. Bioscience Reports 28:161-175, 2008
  52. Nikolova D, Asangani I, Nelson L, Hughes D, Siwak D, Mills G, Harms A, Buchholz E, Pilz L, Manegold C, Allgayer H: Cetuximab attenuates invasion, metastasis, and u-PAR gene expression in non small-cell lung cancer (NSCLC), and u-PAR, besides E-cadherin, is a novel biomarker of Cetuximab sensitivity. Cancer Research 69(6):2461-2670, 2009
  53. Appelt J-U, Giordano F, Ecker M, Roeder I, Grund N, Hotz-Wagenblatt A, Opelz G, Zeller J, Allgayer H, Fruehauf S, Laufs S: QuickMap: A public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Therapy 16(7):885-893, 2009
  54. Bürgy D, Weber T, Maurer G, Leupold J, Mudduluru G, Medved F, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenomas, and carcinoma in thyroid malignancies. International Journal of Cancer 125: 894-901, 2009
  55. Bürgy D, Kambakamba P, Fuchs T, Tang Y, Maurer G, Mudduluru G, Post S, Nakada MT, Yan L, Allgayer H: Prognostic impact of extracellular matrix metalloprotease inducer (EMMPRIN)-immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in the bone marrow of gastrointestinal cancer patients. Cancer 15: 4667-4678, 2009
  56. Wang Q, Sun Z-X, Allgayer H, Yang H-S: Down-regulation of E-cadherin is an essential event in activating ß-catenin/Tcf dependent transcription and expression of target genes in Pdcd4 knock-down cells. Oncogene 29(1):128-138, 2009
  57. Giordano F, Appelt J-U, Zucknick M, Abba M, Zeller WJ, Fruehauf S, Allgayer H, Laufs S: Cold spots in hot spots: transcription start sites of active genes are spared from HIV vector integration. AIDS  23(18): 2535-7, 2009
  58. Lichter P, Allgayer H; Bartsch H, Fusenig N, Hemminki K, von Knebel Doeberitz M, Kyewski B, Miller AB, zur Hausen H: Obligation for cell line authentication: appeal for concerted action. Int J Cancer 126(1): 1, 2010 (Editorial)
  59. Mudduluru G, Vajkoczy P, Allgayer H: Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer.  Mol Cancer Res 8(2): 159-169, 2010 (Highlight of the Issue)
  60. Rasheed SAK, Efferth T, Asangani IA, Allgayer H: Artesunate – first evidence that an anti-malaria drug inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127(6):1475-85, 2010
  61. Ceppi P, Mudduluru G, Regalla K, Rap I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small-cell lung cancer. Mol Cancer Res  Sept 8(9): 1207-16, 2010 Highlight of the Issue
  62. Körner A, Mudduluru G, Manegold C, Allgayer H: Enzastaurin inhibits invasion and metastasis in lung cancer via diverse molecules. Brit J Cancer sept 7, 103(6):802-11, 2010
  63. Grund N, Maier P, Giordano FA, Appelt JU, Zucknick M, Li L, Wenz F, Zeller WJ, Fruehauf S, Allgayer H, Laufs S: Analysis of lentiviral SIN vector integration sites and flanking gene expression in human peripheral blood progenitor cells following alkylator chemotherapy. Human Gene Therapy Aug 21(8):943-56, 2010
  64. Mudduluru G, Leupold JH, Stroebel P, Allgayer H: PMA up-regulates the transcription of Axl by AP-1 transcriptioni factor binding to TRE sequences via the MAPK cascade in leukaemia cells. Biology of the Cell 103, 21-33, 2010
  65. Jeltsch K, Radke T, Laufs S, Giordano F, Allgayer H, Wenz F, Zeller WJ, Kogler G, Maier P: USSC (unrestricted somatic stem cells): Interaction with CD34+ cells in vitro and in vivo – Expression of “homing genes” – Exclusion of tumorigenic potential. Cytotherapy Mar 13(3): 357-65, 2011
  66. Mudduluru G, Nesson George-William JN, Muppala S, Asangani IA, Regalla K, Nelson LD, Allgayer H: Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Bioscience Reports 31(3): 185-97, 2011
  67. Meseguer S, Mudduluru G, Escamilla JM, Allgayer H*, Barettino D*: Micro-RNAs-10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). Journal of Biol Biochemistry Feb 11 286(6):4150-64, 2011 (*shared senior authorship)
  68. Mudduluru G, Ceppi P, Regalla K, Scagliotti GV, Papotti M, Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.  Oncogene. 2011 Jun 23;30(25):2888-99.
  69. Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S,  Roeder I, Kleff V, Zeller WJ, Allgayer H, von Kalle C, Fruehauf S, Moritz T, Laufs S: Clonal inventory screens uncover monoclonality following serial transplantation of MGMTP150K transduced stem cells and dose-intense chemotherapy. Human Gene Therapy, 2011
  70. Allgayer H, Hart IR: Editorial: Special Section “Site-Specific Metastasis”. Int J Cancer 128: 2509-2510, 2011 (Editorial)
  71. Regalla K, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer Jun 1, doi: 10, 1002, 2011 [Epub ahead of print]
  72. Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP: CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci. 2011 Jun 28. [Epub ahead of print]
  73. Heckmann D, Laufs S, Maier P, Zucknick M, Giordano FA, Veldwijk MR, Eckstein V, Wenz F, Zeller JW, Fruehauf S, Allgayer H: A lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1a-induced migration and invasion. Onkologie 34:502-508, 2011
  74. Abba M, Laufs S, Aghajany M, Wu H, Korn B, Benner A, Allgayer H: Look who’s talking: decoding differentially regulated epithelial and stromal pathways in colorectal cancer. Cancer Genomics & Proteomics 9: 15-26, 2012
  75. Leupold JH, Asangani IA, Mudduluru G, Allgayer H: Promoter cloning and characterization of the human programmed cell death protein 5 (pdcd4) gene: Evidence for ZBP-89 and Sp binding motifs as essential Pdcd4-regulators. Bioscience Reports 32(3): 281-297, 2012
  76. Daidone MG, Foekens JA, Harbeck N, Martens J, Brunner N, Thomssen C, Hall JA, Salgado R, Dittmer J, Geurts-Moespot A, Duffy MJ, Sweep FCGJ, Schmitt M, EORTC PathoBiology Group (H. Allgayer Group Member): Identification, validation and clinical implementation of cancer biomarkers: Translational studies of the EORTC PathoBiology Group. Eur J Cancer 9, No. 2, 120-127, 2012
  77. Rotert JV, Hohenberger P, Nowak K, Leupold JH, Allgayer H: Src activity is increased in gastrointestinal stromal tumors — analysis of associations with clinical and other molecular tumor characteristics. Submitted 2011
  78. Keklikoglou  I, Koerner C, Schmidt C, Zhang JC, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A et al: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-ß signaling pathways. Oncogene, in press 2011

Reviews

  1. Allgayer H, Heiss MM, Schildberg FW: Prognostic parameters in gastric cancer: Review. Brit J Surgery 84: 1651 - 1664, 1997.
  2. Allgayer H, Heiss, MM: Die minimal residuale Tumorerkrankung. Prognostische Aussagekraft und therapeutische Konsequenz (Eingeladenes Review). Originalienband der Münchener Medizinischen Wochenschrift, IV/2000, pp.1-4, 2001.
  3. Allgayer H, Boyd DD, Lengyel ER, Heiss MM: The urokinase-receptor – Molecular regulation and clinical significance. (Eingeladenes Review). Res Adv Cancer 1: pp.85-97, 2001.
  4. Allgayer H:  Erfassung einer potenziell minimal residualen Tumorerkrankung bei soliden Tumoren – Chancen und Grenzen (Eingeladenes Review). AKODH (Zeitschrift für naturheilkundliche Onkologie) 9: 6-10, 2002.
  5. Heiss MM, Allgayer H: Kongressbericht: Molekulares Staging von Karzinomen. Deutsches Ärzteblatt 33: 1868 – 1870, 2002
  6. Heiss MM, Allgayer H: Molekulares Staging von Karzinomen. Onkologie 2002, 25;371.384, 2003
  7. Allgayer H:  Molecular regulation of urokinase-receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy. In: Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, pp. 15-30, Springer Verlag (Berlin, Heidelberg, New York) 2003.
  8. Allgayer H, Heiss MM, Schildberg FW:  Summary and Congress Report: Molecular Staging of Cancer ---- Concepts of Today, Therapies of Tomorrow. In: Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, pp. 211-217, Springer Verlag (Berlin, Heidelberg, New York) 2003.
  9. Fuchs T, and Allgayer H: Transcriptional regulation of the urokinase-receptor (invited review). Biol Chem. 384(5):755-61, 2003.
  10. Allgayer H, and Lengyel ER: Urokinase and its Receptor --- Essential Players in Metastasis (invited review), in press.
  11. Allgayer H: Etablierung und Führung einer Tumorbank. In: Manegold, C (Hrsg): Therapieoptionen beim nicht-kleinzelligen Lungenkarzinom. UNI-MED Verlag AG, 2005, pp. 144-150
  12. Allgayer H: Regulation and clinical significance of urokinase receptor (u-PAR), an invasion related molecule. Z. Gastroenterol 44: 1-9, 2006
  13. Laufs S, Schumacher J, Allgayer H: Urokinase receptor (u-PAR) – an essential player in multiple games of cancer. A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome, in minimal residual disease. Cell Cycle (2006) 5(16):1760-71
  14. Allgayer H: Review on the EACR Young Cancer Researcher Award Lecture, ECCO 13-Meeting, 2005. EACR News Letter, European Association of Cancer Research, Nottingham/UK. EACR Newsletter 4-5, 2006
  15. Allgayer H: Ein Meilenstein translationaler Forschung. Kommentar zur Studie von Olaussen KA et al. Focus Onkologie 1-2:20-21, 2007
  16. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE: Tumor-associated proteolytic factors uPA and PAI-1: Critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.   Crit Rev in Clin Lab Sciences 44(2):179-201, 2007
  17. Allgayer H: Die „customized  therapy“ ist im Kommen. Kommentar zur Studie von Cobo et al. Focus Onkologie 12: 20-21, 2007
  18. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N: The urokinase-system – role of cell proliferation and apoptosis. Histol Histopathol 23:227-236, 2008
  19. Schlotter CM, Vogt U, Allgayer H, Brandt B: Molecular targeted therapies for breast cancer treatment. Breast Cancer Research 10:211, 2008
  20. Laufs S, Blier S, Maier P, Wenz F, Zeller J, Frühauf S, Allgayer H: Multiple displacement amplification enables large scale clonal analysis following retroviral gene therapy. J Virology 82(5): 2448-2455, 2008
  21. Allgayer H, Aguirre-Ghiso J.A.: The urokinase receptor (u-PAR) - a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116:602-14, 2008
  22. Allgayer H, Fulda S: An introduction to molecular targeted therapy. Advances in Medical Sciences, Vol. 53,  2008
  23. Abba M, Allgayer H: (Invited Review): Micro-RNAs as regulatory molecules in cancer: A focus on models defining MiRNA functions. Drug Discovery Today: Disease Models, Vol. 6, No. 1, 13-19, 2009
  24. Allgayer H: EGFR-Genamplifikation: ein vielversprechender Marker. Kommentar zur Arbeit Hirsch FR et al. Fokus Onkologie, 1-2, 20-21.
  25. Hildenbrand R., Schaaf A., Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P: Tumor stroma ist he predominent uPA-, uPAR-, PAI-1-expressing tissue in human breastcancer: prognostic impact. Histol Histopathol 2009, 24: 869-877.
  26. Allgayer H: (Invited Review): Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev. Oncol/Hematol 73: l185-191, 2010
  27. Allgayer H: (Invited Review for Dr. Patricia Steeg): Translational research on u-PAR. Eur J Cancer 46: 1241-1251, 2010
  28. Hildenbrand R, Allgayer H, Marx A, Stroebel P: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs 19(5): 641-652, 2010
  29. Abba M, Patil N, Allgayer H: WX-671, a serine protease inhibitor for the potential treatment of solid tumors. In press 2011
  30. Abba M, Mudduluru G, Allgayer H: MicroRNA in cancer: Small molecules, big chances. Anti Cancer Agents in Medical Chemistry. In press 2011

Book Chapters & Conference Proceedings

  1. Allgayer H, Heiss MM, Babic R, Grützner KU, Jauch KW, Schildberg FW: Definition funktioneller Risikofaktoren beim Magenkarzinom durch das Urokinase-System. in: Trede et al. (ed.): Chirurgisches Forum 1994 f. experim. und klinische Forschung, Springer-Verlag Berlin-Heidelberg, pp. 353-357, 1994 (Conference Proceedings)
  2. Heiss MM, Allgayer H, Babic R, Grützner U, Jauch KW, Schildberg FW: Prognostic value of new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.     in: Wangsteen O (ed.): American College of Surgeons, Surgical Forum, 80th Annual Clinical Congress, Vol. XLV, pp. 482-485, 1994. (Conference Proceedings)
  3. Allgayer H, Heiss MM, Babic R, Löhrs U, Schildberg FW, Jauch KW: Functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. In: Nishi M, et al. (ed.): 1st Int Gastric Canc Congr, Kyoto, Japan, March 29 - April 1, 1995: pp. 427-430, Monduzzi Edi (Bologna), 1995. (Conference Proceedings)
  4. Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Schildberg FW: Differentielle Bedeutung des Urokinase-Systems für die Prognose des Magenkarzinoms. in: Trede et al. (ed.): Chirurgisches Forum 1996 f. experim. und klinische Forschung, Springer-Verlag Berlin-Heidelberg, pp. 377 – 381, 1996. (Conference Proceedings)
  5. Allgayer, H, Heiss MM, Schildberg FW, et al.: Neue Prognosefaktoren beim gastrointestinalen Karzinom. in: Roder JD (Ed.): Tumormanual Gastrointestinale Tumoren des Tumorzentrums Muenchen 1997.
  6. Heiss MM, Allgayer H, Babic R, Grützner KU, Löhrs U, Jauch KW, Schildberg FW: Funktionelles Staging des Magenkarzinoms – Eine neue Sichtweise durch Einbeziehung der früh­systemischen Komponente und tumor-assoziierter Proteolysesysteme. In Langenbecks Arch Chir Suppl II (Kongreßbericht). Springer Verlag Berlin-Heidelberg, pp. 1465-1466, 1997 (Conference Proceedings)
  7. Heiss MM, Allgayer H, Grützner KU, Jauch KW, Schildberg FW: Proposal of a new biological staging model in gastric cancer considering biological grading and minimal residual tumor disease. In: Wangensteen OH (ed). Surgical Forum, 83rd Ann Clin Congr Chicago, pp. 845 - 848, 1997 (Conference Proceedings) 
  8. Beyer BCM, Allgayer H, Pietsch AR, Heizmann O, Grützner KU, Schildberg FW, Heiss MM:Tumor-assoziierte Proteolyse und Prognose: Validierung der Bedeutung des Urokinase-Systems beim Magenkarzinom zum präoperativen Staging. In: Enke A, et al (Hrsg). Langenbecks Arch Chir, Chirurg Forum 2000 f experim u klin Forschung. Springer Verlag Berlin-Heidelberg, pp. 89-92, 2000 (Conference Proceedings)
  9. Pietsch AR, Allgayer H, Beyer BCM, Grützner KU, Lau-Werner UM, Schildberg FW, Heiss MM: Minimal residuale Tumorerkrankung beim kolorektalen Karzinom: Prognostische Bedeutung des perioperativen Tumorzellnachweises und folgender Verlaufsuntersuchungen. In: Enke A, et al (Hrsg). Langenbecks Arch Chir, Chirurg Forum 2000 f experim u klin Forschung. Springer Verlag Berlin-Heidelberg, pp. 119-121, 2000 (Conference Proceedings)
  10. Allgayer H, Lengyel ER, and Boyd D: Transcriptional regulation of proteases. (Eingeladener Beitrag). In: Muschel R (Ed.): Proteases and their inhibitors in cancer metastasis. Kluwer 2001
  11. Allgayer, H, Heiss MM, Schildberg FW, et al.: Neue Prognosefaktoren beim   gastrointestinalen Karzinom. in: Heiss MM (Ed.): Tumormanual Gastrointestinale Tumoren des Tumorzentrums Muenchen, Neuauflage 2001.
  12. Allgayer H: Clinical recommendations for diagnosis, treatment and follow-up of non-small cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma. CSC „Petro Ofsetas“, LT-Vilnius, 2006 (Conference Proceedings)
  13. Brandt B,  Vogt U, Allgayer H: Neue molekulare Perspektiven. In: Schlotter CM, Bonk U (eds): Individualisierte Konzepte der primär systemischen und adjuvanten Therapie des Mammakarzinoms – Gen und Genexpression. UNIMED Verlag, 2007
  14. Allgayer H: Establishing a tumor tissue bank: An interdisciplinary challenge. In: Manegold, C (ed): Therapeutic options in non-small cell lung cancer. UNI-MED Verlag AG, 2007, pp 23-29
  15. Allgayer H: General insights into tumor invasion, progression, and metastasis. In: Allgayer H, Rehder H, Fulda S (eds): Hereditary Tumors. Wiley Blackwell 2008, pp. 3-24
  16. Allgayer H, Fulda S: Molecular targeted therapy. In: Allgayer H, Rehder H, Fulda S (eds): Hereditary Tumors. Wiley Blackwell 2008, pp. 501-514
  17. Leupold JH, Allgayer H: Plasminogen activators and their inhibitors in cancer. In: Behrendt N (ed): Matrix Proteases in Health and Disease, ????, pp. 227-249

Books

  1. Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, ISBN 3-540-43469-0, Springer Verlag (Berlin, Heidelberg, New York) 2003.
  2. Allgayer H, Manegold C, Post S, Heiss MM, Poustka A, Wiestler O: Kongressband “Molecular Staging of Cancer“, European Journal of Cancer  Vol. 4, No. 6, 2006
  3. Allgayer, H, Rehder, H, Fulda, S, (eds): Hereditary Tumors. From genes to clinical consequences. Wiley VCH 2008
  4. Allgayer H: Establishing a tumor tissue bank: An interdisciplinary challenge. In: Manegold, C (ed): Therapeutic options in non-small cell lung cancer. UNI-MED Verlag AG, 2010, second edition, pp 23-29

Abstracts

  1. Heiss MM, Babic R, Allgayer H, Grützner KU, Löhrs U, Schildberg FW: Korrelation von klinischem Verlauf und immunhistochemischem Nachweis von Urokinase-Typ Plasminogenaktivator (u-PA), dem Rezeptor (u-PAR) und Inhibitor Typ 1 (PAI 1) an Magenkarzinomen. Verhandlungen der Deutschen Gesellschaft für Pathologie 77: 528, 1993
  2. Heiss MM, Jauch KW, Gruetzner KU, Allgayer H, Funke I, Schildberg FW: Prognostic value and fate of bone-marrow micrometastasis in curatively resected gastric cancer patients. Pan-Pacific Surgical Association, 22nd Congress, 31.1.- 4.2.1994, Hong Kong, 1994
  3. Heiss MM, Allgayer H, Babic R, Grützner U, Jauch KW, Schildberg FW: Prognostic impact of urokinase-type plasminogen-activator system expression increases with tumor dedifferentiation in gastric cancer. Eur J Surg Oncol 20(3):361 – 362, 1994
  4. Allgayer H, Heiss MM, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Prognostic significance of uPA-receptor-expression by disseminated tumour cells. in: Benrad et al. (ed.): Clinical Applications of the plasminogen activator system in cancer. Finsen Laboratory, Copenhagen, p. 30, Nov. 1995.
  5. Heiss MM, Allgayer H, Gruetzner KU, Schildberg FW, Jauch KW: Prognostischer Wert und Längsschnittverlauf von Mikrometastasen im Knochenmark        beim resezierten Magenkarzinom. in: Hohenberger W, Wittekind C (ed.): Wertigkeit zytologischer Untersuchungen beim   Staging solider Tumoren. Workshop. Erlangen, p. 7, Dez. 1995.
  6. Jauch KW, Heiss MM, Babic R, Allgayer H, Löhrs U, Schildberg FW: Functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. First Int Gastric Canc Congr, Kyoto, Japan, (Proceedings), p. 72, 1995
  7. Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Löhrs U, Schildberg FW: Expression of tumor-associated proteases and their inhibitors in gastric cancer: Impact on prognosis. AACR Proceedings 36, p. 93, 1995.
  8. Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Schildberg FW: Expression of uPA-receptor on disseminated tumor cells in bone marrow - evidence for the metastatic phenotype in minimal residual tumor disease. Proceedings of the AACR Conference Proteases and Protease Inhibitors, Panama City, Florida, March 1996.
  9. Heiss MM, Allgayer H, Grützner KU , Babic R, , Jauch KW, Löhrs U, Schildberg FW: Functional staging in gastric cancer - new aspects by bone marrow micrometastases and tumor-associated proteases. Eur J Surg Onc 22(4): 407, 1996.
  10. Allgayer H, Heiss MM, Babic R, Jauch K-W., Schildberg FW: Expression des uPA-Rezeptors auf disseminierten Tumorzellen des Knochenmarks - erster Hinweis auf den metastatischen Phänotyp einer minimal residualen Tumorkomponente beim soliden Karzinom. Wis­senschaftl. Referate, Vereinigung Bayerischen Chirurgen e.V., Würzburg, pp. 33, 1996
  11. Allgayer H, Grützner KU, Simon W, Babic R, Schildberg FW, Heiss MM: Urokinase-Rezeptor als Charakeristikum des metastatischen Phänotyps minimal residualer Tumorzellen beim soliden Karzinom. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, Mün­chen, 275-276, 1996
  12. Beyer BCM, Babic R, Allgayer H, Grützner KU. Schildberg FW, Heiss MM: Neue funktionelle Prognosefaktoren des Magenkarzinoms - definiert durch tumorassoziierte Proteolyse­systeme. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, München, pp. 276-277, 1996
  13. Heiss MM, Allgayer H, Grützner KU, Jauch KW, Schildberg FW: Prognostischer Wert und Längsschnittverlauf von Mikrometastasen im Knochenmark bei resezierten Ma­genkarzinom. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, München, 277-278, 1997
  14. 14. Heiss MM, Allgayer H, Grützner KU, Babic R, Jauch KW, Schildberg FW: Functional staging in gastric cancer - New aspects through bone marrow micrometastases  and tumor-associated proteases. Int Symposium „Proteases and Cancer“ (Biomed-1 Meeting), Heidelberg, Abstract No. 6, 1997
  15. Heiss MM, Allgayer H, Jauch KW, Funke I, Gruetzner U, Schildberg FW: Neue Prognosefaktoren beim Magenkarzinom. WissenschaftlicheAusstellung zum 114. Kongress der Deutschen Gesellschaft fuer Chirurgie in München, 1997.
  16. Stroehlein MA, Fraunberger P, Stets R, Allgayer H, Tarabichi A, Delanoff C, Grützner KU, Wustrow T, Schildberg FW, Heiss MM: Blood transfusion effects on predominant Th1 or Th2 type helper cell response in cancer surgery. Proc Am Assoc Can Res, San Diego, USA 795:119, 1997
  17. Allgayer H, Wang H, Boyd D: Regulation of the expression of the urokinase-type plasminogen activator gene by AP-2. AACR Proceedings 39: 492, 1998
  18. Allgayer H, Wang H, Boyd DD: Downregulation of urokinase-type plasminogen activator receptor (u-PAR) in a highly invasive colon cancer cell line made to express a dominant negativeAP-2 is mediated by a motif bound with an AP-2-like protein, Sp1 and Sp3 and is associated with reduced extracellular matrix degradation. Proceedings of the Metastasis Research Society, VII International Congress, Oct. 7-10, 1998, San Diego, Ca, USA, p. 34, 1998.
  19. Beyer BCM, Allgayer H, Babic R, Grützner KU, Tarabichi A, Heiss MM, Schildberg FW: Die prognostische Bedeutung von MMP-2 beim Magenkarzinom, sowie ein therapeutischer Ansatz mit Marimastat beim inoperablen (lokal fortgeschrittenen bzw. metastasierten) Stadium. 4. Wissenschaftl. Seminar des Klinikums Großhaderns, Univ. Int. Di Venezia, Italien: 25, 1998
  20. Pietsch AR, Allgayer H, Grützner KU, Lau-Werner U, Heiss MM, Schildberg FW: Die prognostische Bedeutung disseminierter Tumorzellen beim colorektalen Karzinom: Perioperativer Nachweis und Längsschnittuntersuchung. 4. Wissenschaftl. Seminar des Klinikums Großhaderns, Univ. Int. Di Venezia, Italien: 26, 1998
  21. Heiss MM, Pietsch AR, Allgayer H, Grützner KU, Schildberg FW: Prognostic significance of disseminated tumour cells in colorectal cancer: Perioperative state and follow-up. Langenbeck Arch Surg 383,5:36,1998
  22. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD: Transcriptional induction of the urokinase-receptor (u-PAR) gene by a constitutively active Src: Requirement of an upstream motif (-152/-135) bound with Sp1. AACR Proceedings 40, Abstract 1311, 1999.
  23. Heiss MM, Babic R, Grützner KU, Tarabichi A, Schildberg FW, and Allgayer H: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. Eur J Cancer 35 (Suppl. 5): 15, 1999.
  24. Allgayer H, Wang H, Gallick GE, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Urokinase-receptor expression is transcriptionally induced by Src via an upstream element (-152/-135) bound with Sp1. Eur J Cancer 35 (Suppl. 5): 13, 1999.
  25. Heiss MM, Babic R, Grützner KU, Tarabichi A, Schildberg FW, and Allgayer H: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. Langenbeck´s Arch Surg 384 (5): 500, 1999.
  26. Allgayer H, Wang H, Gallick GE, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Urokinase-receptor expression and proteolysis is transcriptionally induced by Src: A proposal for Src as a target for anti-invasive therapy in colon cancer. Langenbeck´s Arch Surg 384 (5): 504, 1999.
  27. Heiss MM, Allgayer H, Babic R, Grützner KU, Schildberg FW: Identification of high risk patients in gastric cancer by specific tumor–associated protease patterns. Lan­genbeck Arch Surg 384, 1:94, 1999
  28. Heiss MM, Allgayer H, Grützner KU, Babic R, Jauch KW, Schildberg FW: Erweitertes biologisches Staging durch Mikrometastasen und tumorassoziierte Proteasen beim Magenkar­zinom. Acta Chirurgica Austriaca, 31(Suppl 155):7, 1999
  29. Heiss MM, Simon E, and Allgayer H: Untersuchung zur Expression des Urokinase-typ Plasminogen Aktivator-Rezeptors (uPA-R) auf dissemi­nierten Tumorzellen als Indikator einer klinisch relevanten minimal residualen Tumorkomponente beim Magenkarzinom. Doktorandenkolloquium der Chir. Forschung Freiburg und der Chir. Forschung der LMU München, Freiburg, 1999
  30. Beyer BCM, Allgayer H, Pietsch AR, Heizmann O, Wustrow TPU, Grützner KU, Schildberg FW, Heiss MM (2000): Tumor-associated proteolysis and prognosis: Validation of the urokinase system in the preoperative staging of gastric cancer.  Proc Am Assoc Cancer Res 41:3283, 2000
  31. Allgayer H, Wang H, Shirasawa T, Sasazuki T, Heiss MM, Schildberg FW, Boyd DD: Inhibition of Urokinase receptor (uPA-R) expression and uPA-R-mediated proteolysis in colon cancer by targeted disruption of the K-ras oncogene. Proc Am Assoc Cancer Res 41:1301, 2000
  32. Allgayer H, Wang H, Gallick GE, Crabtree A, Heiss MM, Schildberg FW, Boyd DD: Induction of u-PAR expression in colon cancer bySrc via Sp1 transcription factor. ISOBM 2000 Proceedings (From Tumor Biology to Clinical Oncology), Karger (Basel, Freiburg, Paris, London), p. 126, 2000.
  33. Allgayer H, Wang H, Gallick GE, Crabtree A, KrakerAJ, Heiss MM, Schildberg FW, Boyd DD: Transkriptionale Induktion der Expression und Funktion des Urokinase-Rezeptors (u-PAR) beim Colonkarzinom durch das c-src Onkogen via Sp1 – erste Hinweise auf die Inhibition von Src als mögliche anti-metastatische Therapie. Vereinigung der Bayerischen Chirurgen – Wissenschaftliche Referate der 77. Tagung (Hrsg: Jauch KW, Bauer H, Metak G): p. 29, 2000
  34. Allgayer H, Wang H, Gallick GE, Crabtree A, KrakerAJ, Heiss MM, Schildberg FW, Boyd DD: Transkriptionale Regulation von Urokinase-Rezeptor durch das c-src Onkogen. in: Enders G, Meissner F, Peters J, Messmer K (Hrsg.): Research Festival 2000. P. 22, 2000.
  35. Allgayer H, Boyd DD, Heiss MM, Curley SA, and Gallick GE.: Elevated Src kinase activity in primary colorectal cancer is a new biological indicator of a poor clinical prognosis. Proc Am Assoc Cancer Res 42:577, 2001.
  36. Schewe D, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW, and Allgayer H: Transcription factor binding to region –152/-135 of the urokinase receptor (U-PAR) gene: First analysis of a clinical relevance in gastrointestinal carcinomas. Proc Am Assoc Cancer Res 42: 618, 2001.
  37. Allgayer H, Gallick GE, Wang H, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Transcriptional regulation of urokinase receptor expression in colon cancer by Src via Sp1 – Src inhibition as a potential anti-metastatic therapy? Anticancer Research, Abstracts of the IIAR conferences 2001, vol.21(3A): p. 1625, 2001
  38. Schewe D, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW, Allgayer H: Bindung von Transkriptionsfaktoren an Region –152/-135 des Urokinase-Rezeptor (u-PAR)-Gens: Erste Analyse einer klinischen Relevanz in gastrointestinalen Karzinomen. Wiss Referate 78. Tagung der Vereinigung der Bayerischen Chirurgen (Hrsg. V. Bühren), Gerhard Metak Verlag, S. 22
  39. Allgayer H: Gemeinsame Regulatoren von Matrix-Metalloproteinasen und Urokinase-Rezeptor – molekulare Strategien von Tumorzellen zur Erlangung des invasiven Phänotyps. Matrix-Metalloproteinasen- DFG-Workshop Bielefeld, März 2001, Abstractband, S. 7
  40. Allgayer, H: Molecular regulation of urokinase-receptor (u-PAR) gene expression in colon cancer – potential therapeutic and clinical significance. Proceedings of the 2nd general meeting of the International Proteolysis Society (IPS), Oct. 31st  – Nov 4th, Freising, p. L82, 2001
  41. Allgayer H, Schewe DM, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Beyer BCM, Schildberg FW, Heiss MM: Identification of a subpopulation of gastrointestinal cancer patients with tumor-specific transactivation of u-PAR-gene expression via an AP-2/Sp1 promoter motif. Proceedings, CAMO, Chirurgische Forschungstage Halle/Saale, 2001
  42. Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, and Allgayer H: Evidence of an independent prognostic relevance of urokinase-receptor expression by disseminated tumor cells in the bone marrow in a large prospective patient series. Proceedings, CAMO, Chirurgische Forschungstage Halle/Saale, 2001
  43. Allgayer H:  Molecular regulation of urokinase-receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001
  44. Heiss MM, Allgayer H, Grützner KU, Babic R, Schildberg FW: Molecular staging of gastric cancer: Definition of new prognostic subgroups by biological tumor markers. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001
  45. Gallick GE, Allgayer H, Parikh NU, Herynk M, Minard ME: Signal transduction intermediates as prognostic markers and targets for therapeutic intervention in colorectal carcinoma. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001
  46. Grützner KU, Pietsch A, Beyer BCM, Allgayer H, Heiss MM, Schildberg FW: Minimal residual disease as a potential staging entity in colorectal cancer. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001
  47. Schewe DM, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW,  Allgayer H: First clinical evidence of tumor-specific transcription factor binding to region –152/-135 of the urokinase-receptor (u-PAR) gene in resected gastrointestinal carcinoma tissues. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2002
  48. Leupold JH, Colburn NH, Yang HS, Lengyel E, Schildberg FW, Heiss MM, Allgayer H: First evidence for the new tumor suppressor Pdcd4 as a regulator of u-PAR, an invasion-related gene. Proc Am Assoc Cancer Res 43: 622, 2002.
  49. Allgayer H:  Transcriptional regulation of the urokinase-receptor (invited abstract). Proceedings of the ISFP/IFRS-Meeting, p.38, 2002.
  50. Allgayer H, Boyd DD, Heiss MM, Curley SA, Gallick GE: Erstnachweis der übermässigen Aktivität des Protoonkogen-Produktes Src als neuer und unabhängiger Prognosefaktor in einer Serie colorektaler Karzinome. Proceedings, Chirurgische Arbeitsgemeinschaft für Molekulare Onkologie (CAMO), p. 25-3, 2002.
  51. Leupold JH, Colburn NH, Yang HS, Boyd DD, Lengyel ER, Jauch KW, Allgayer H: Erster Hinweis auf eine Rolle des neu beschriebenenen Tumor –Suppressorgens Pdcd4 als Regulator des Invasionsmoleküls Urokinase Rezeptor. Proc Kongress Deutsche Gesellschaft für Chirurgie 2003
  52. Biller T, Schewe DM, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, Allgayer H: First ex vivo analysis of AP-1-family members bound to region –190/-171 of the urokinase receptor (u-PAR) gene in a large cancer patient series. Proceedings (1st edition) of the American Association for Cancer Research (AACR), #1944, 2003
  53. Biller T, Schewe DM, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, Allgayer H: First ex vivo analysis of AP-1-family members bound to region –190/-171 of the urokinase receptor (u-PAR) gene in a large cancer patient series. Proceedings (2nd edition) of the American Association for Cancer Research (AACR), R1944, p. 382, 2003
  54. Allgayer H: Frau Dr. med. Irmgard Graute-Oppermann --- das Leben einer Chirurgischen Pionierin. Deutsche Gesellschaft für Chirurgie—Mitteilungen 3/2003, S. 278. Demeter Verlag (Berlin), 2003
  55. Schewe DM, Biller T, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW,  Allgayer H: Erste in vivo Analyse von Subgruppen mit einer tumor-spezifischen Transkriptionsfaktorbindung an den Urokinase-Rezeptor Promotor (u-PAR) in einer grossen Serie gastrointestinaler Karzinome.           Deutsche Gesellschaft für Chirurgie, Proceedings 121. Jahreskongress, 2004.
  56. Fuchs T, Grützner KU, Simon E, Jaeger M, Heiss MM, Schildberg FW, Jauch KW, Allgayer H.: Immunocytochemical phenotyping of minimal residual disease—identification of clinically relevant potential therapeutic targets. Proceedings of the American Association for Cancer Research (AACR) 2004, p. 430.
  57. Allgayer H: Regulators of the urokinase-receptor—potential relevance for the clinic and in vivo. Angiogenesis, vol.7 suppl.1: p.52, 2004.
  58. Maurer GD, Leupold JH, Schewe DM, Biller T, Hornung HM, Grützner KU, Lau-Werner U, Post S, Allgayer H: Induction of urokinase-receptor (u-PAR) gene expression via Src and two different u-PAR-promoter elements: First analysis of in vivo and prognostic relevance in resected colorectal carcinomas. Proceedings of the American Association for Cancer Research (AACR) 2005, abstr. 1268.
  59. Leupold JH, Lengyel ER, Post S, Allgayer H: Src-induced uPAR gene expression is also mediated via an AP-1 motif and is associated with increased invasive capacity in vivo. Proceedings of the American Association for Cancer Research (AACR) 2005, abstr. 4526.
  60. Allgayer H: Molecular regulation of an invasion-related molecule – options for tumor staging and clinical strategies.  EACR Proceedings of the ECCO 13-Congress 2005
  61. Asangani IA, Leupold HH, Gil-Parrado S, Post, S, Allgayer H: Promoter characterization of human small regulatory subunit calpain, CSS1. Proceeding of the American Association for Cancer Research (AACR) 2006, abstract no. 877
  62. Beyer BCM, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H: Urokinase-system expression in gastric cancer – Confirmation of prognostic impact in an independent patient series and first evidence for a predictor in preoperative biopsies and intestinal metaplasia. Proceeding of the American Association for Cancer Research (AACR) 2006, abstract no. 4366
  63. Medved F, Grobholz R, Jost C, Mudduluru G, Leupold JH, Schumacher J, Colburn NH, Post S, Allgayer H:  Evidence of Pdcd4 as a novel marker for tumor diagnosis and progression in resected colorectal carcinomas. EACR Congress, Budapest, 01.-04.06.2006
  64. Allgayer H: Welcome Address: 2nd International Congress on Molecular Staging of Cancer, June 22-26, 2006 in Heidelberg. European Journal of Cancer 4, No. 6,  p. 1 Suppl 2006
  65. Allgayer H: Specific transcriptional regulators of the u-PAR gene – in vivo and clinical relevance, and first suggestions for molecular tumor staging. European Journal of Cancer 4, No. 6, p. 6 Suppl 2006
  66. Kates R, Allgayer H, Harbeck N: Hierarchical neural net technology for molecular staging with clinical data. European Journal of Cancer 4, No. 6, p. 9 Suppl 2006
  67. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H: Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2?-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers: European Journal of Cancer 4, No. 6, p. 28 Suppl 2006
  68. Leupold JH, Yang H-S, Colburn NH, Boyd DD, Lengyl ER, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (u-PAR) gene expression via Sp-transcription factors: European Journal of Cancer 4, No. 6, p. 28 Suppl 2006
  69. Medved F, Grobholz R, Jost C, Mudduluru G, Leupold JH, Schumacher J, Colburn NH, Post S, Allgayer H: Evidence of Pdcd4 as a novel marker for tumor diagnosis and progression in resected colorectal carcinomas: European Journal of Cancer 4, No. 6, p. 28-29 Suppl 2006
  70. Mudduluru G, Post S, Allgayer H: Preliminary promoter characterization of the gene for the human receptor tyorsine kinase AXL: European Journal of Cancer Suppl, in press
  71. Asangani IA, Leupold JH, Gil-Parado S, Post S, Allgayer H: Promoter characterization of human small regulatory subunit calpain, CSS1: European Journal of Cancer 4, No. 6, p. 37 Suppl 2006
  72. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung H-M, Lau-Werner U, Post S, Allgayer H: Transcriptional and molecular regulators of the urokinase-receptor-(u-PAR)-gene: First analysis of independent prognostic relevance in resected colorectal cancer: European Journal of Cancer 4, No. 6, p. 52-53 Suppl 2006
  73. Bleier S, Laufs S, Sorg U, Kleff V, Flasshove M, Allgayer H, Seeber S, Zeller WJ, Fruehauf S, Moritz T: Clonal analysis of hematopoietic stem cells after serial transplantation of animals receiving MGMTP140K gene transduced cells following chemotherapy. European Society of Gene  Therapy 2006, Prag.
  74. Leupold JH, Bach F, Post S, Allgayer H: Essential u-PAR promoter cis-element as a tool for targeting metastatic tumor cells. Langenbecks Arch. Surg 391: 513-543, 2006
  75. Mudduluru G, Post S, Allgayer H: Sp1 and Sp3 mediate transcription of the human receptor tyrosine kinase AXL Gene. Proceedings of the American Association for Cancer Research, 2007
  76. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH,  Post S, Jansen A, Colburn NH, Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition and is an independent prognostic factor in colorectal cancer. Proceedings of the American Association for Cancer Research, 2007
  77. Giordano FA, Appelt J-U, Zimmermann M, Weinhardt S, Wagenblatt A, Allgayer H, Zeller WJ, Fruehauf S, Laufs S: The GTSG.org Database: A first meta-analysis of more than 11.300 retroviral gene therapy vector insertion sites.  American Society of Gene Therapy, Seattle 2007
  78. Nikolova, DA, Asangani IA, Rasheed SAK, Harms A, Post S, Manegold C, Allgayer H: Cetuximab attenuates EGF induced u-PAR expression in NSCLC. Eur J Cancer Vol 5, No. 4, 367-368
  79. Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Proceedings 6th Annual AACR International Conference “Frontiers in Cancer Prevention Research”, December 5-8, 2007, Philadelphia/USA, pp. 186
  80. Rasheed S, Efferth T, Post S, Nelson N, Hughes DPM, Mills GB, Allgayer H: Artesunate decreases invasion of non-small cell lung cancer. Proceedings Annual Meeting American Association for Cancer Research, San Diego, April 12-16, 2008, Vol. 49
  81. Nikolova SA, Asangani I, Rasheed S, Nelson L, Hughes DPM, Mills GB, Post S, Buchholz E, Manegold C, Allgayer H: Cetuximab attenuates EGF induced u-PAR expression: study on the anti-metastatic potential of Cetuximab in NSCLC. Proceedings Annual Meeting American Association for Cancer Research, San Diego, April 12-16, 2008, Vol. 49
  82. Allgayer H: Molecular markers 2008: defining targeted therapy in non-small-cell lung cancer (NSCLC). 3rd Euroregional Workshop on Thoracic Oncology: Advances in thoracic cancer treatment WCLC 2008 and ASCO 2008 follow-up. Vilnius, Lithuania, June 20-21, 2008
  83. Rotert, J.V., Hohenberger, P., Leupold, J.H., Allgayer, H: Src activity is increased in liposarcomas and in gastrointestinal stromal tumors – analysis of associations with clinical and molecular tumor characteristics. Eur J Cancer 6(9), 2008
  84. Leupold JH, Asangani I, Post S, Allgayer H: Characterization of the human programmed cell death protein 4 (pdcd4) promoter. Langenbecks Arch Surg 393:759-815, 2008
  85. Körner A, Nikolova D, Mudduluru G, Manegold C, Allgayer H: Enzastaurin inhibits urokinase-receptor (u-PAR) expression in Non-Small Cell Lung Cancer (NSCLC) cells, migration, and invasion. Posterpreis International Thoracic Oncology Congress, Dresden, 01.-05.10.2008
  86. Kirschner MB, Leupold JH, Schmidt K, Post S, Manegold C, Allgayer H: Zoledronic acid treatment leads to reduced invasion and tumor growth of lung cancer cells. International Thoracic Oncology Congress, Dresden, 01.-05.10.2008
  87. Nikolova DA, Asangani IA, Nelson LD, Hughes DPM, Siwak D, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C,  Allgayer H: Cetuximab attenuates invasion,metastasis and u-PAR gene expression in non small cell lung cancer: u-PAR and E-cadherin are novel bio markers of Cetuximab sensitivity. International Thoracic Oncology Congress, Dresden, 01.-05.10.2008
  88. Bleier, S., Maier, P., Grund, N., Appelt, U., Allgayer, H., Zeller, W.J., Fruehauf, S., and Laufs,S. Chemoselection: Does it impact integration patterns and clonal size of gammaretrovirally transduced human bone marrow repopulating cells? Deutsche Gesellschaft für Hämatoligie und Onkologie, Congress 2008
  89. Giordano, F.A., Appelt, J.U., Grund, N., Opelz, G., Zeller, J.W., Allgayer, H., Fruehauf, S., and Laufs, S. The GTSG.org database: A monitoring system for insertion sites of gene therapy vectors used in clinical gene therapy studies. Human Gene Therapy. October 2008, 19(10): 1098-1202.
  90. Grund, N., Maier, P., Appelt, U., Allgayer, H., Wenz, F., Zeller, W. J., Fruehauf, S., and Laufs, S. Chemotherapy pressure: its impact on integration site patterns of lentivirally transduced human hematopoietic stem cells. European Human Gene Therapy. October 2008, 19(10): 1098-1202.
  91. Laufs, S., Giordano, F.A., Appelt, J.U., Roeder, I., Hotz-Wagenblatt, A., Opelz, G., Zeller, W.J., Allgayer, H., and Fruehauf, S. Gene therapy vector insertion site analysis and storage tools. International Society for Cellular Therapy Congress 2008.
  92. Kabeer Rasheed SA, Efferth T, Asangani I, Allgayer H: Artesunate – first evidence that an anti-malaria drug inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. CESAR Annual Meeting, Heidelberg, October 2009
  93. Patil N, Schwarzbach M, Laufs S, Allgayer H: Transforming capacity of FUS-CHOP fusion transcripts – Insight in soft tissue liposarcoma. PhD abstract, DKFZ Heidelberg 2009
  94. Allgayer, H: Concepts, problems and perspectives of targeted and tailored cancer therapy”. Joint 4th EORTC Pathobiology Group Annual Meeting/1st International Multidisciplinary Cancer Research Congress. Antalya/Turkey, May 21-24, 2009.
  95. Heckmann D, Maier P, Wenz F, Zeller WJ, Fruehauf S, Laufs S, Allgayer H: The role of SDF-1?/CXCR4 axis in migration and invasion of colorectal cancer cells in vitro. Poster DGHO-Meeting, Mannheim, October 2009
  96. Leupold JH, Asangani I, Allgayer H: Promoter cloning and characterization of the human programmed cell death protein 4 (Pdcd4) gene: Role of RAR/rxr;L zbp-() AND Sp binding motifs.  Congress of the American Association of Cancer Research (AACR), Denver, April 2009
  97. Nelson L, Mannsperger H, Bender C, Buergy D, Kambakamba P, Mudduluru G, Hughes DP, Van Dyke MW, Allgayer H: Triplex DNA-binding proteins in resected normal and tumor tissues from colorectal cancer patients: biological and clinical relevance. Congress of the American Association of Cancer Research (AACR) Washington, April 2010
  98. Mudduluru G, Ceppi P, Regalla K, Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in cancer cell lines. Congress of the American Association of Cancer Research (AACR) Washington, April 2010
  99. Regalla K, Mudduluru G, Ceppi P, Kozlowski M, Niklinski K, Allgayer H: Mir-30 acts as an anti-metastatic  microRNA and is downregulated in non-small cell lung cancer. Congress of the American Association of Cancer Research (AACR) Washington, April 2010
  100. Heckmann D, Maier P, Zucknick M, Giordano F, Wenz F, Zeller WJ, Fruehauf S, Laufs S, Allgayer H: The role of the SDF1a/CXCR4 axis in invasion of colorectal cancer cells. Congress of the European Association of Cancer Research (EACR) Norway, June 2010
  101. Patil N, Kabeer SA, Schwarzbach M, Laufs S, Allgayer H: First evidence that FUS-CHOP leads to increased invasion and migration via MMPs in liposarcoma. Congress of the American Association of Cancer Research (AACR) Washington, April 2010
  102. Ceppi P, Mudduluru G, Regalla K, Rap I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small-cell lung cancer. EORTC Meeting, Amsterdam, 2010
  103. Udainiya S, Rasheed SAK, Meyer Ch, Leupold JH, Ceppi P, Dooley S, Karunagaran D, Papotti M, Allgayer H: Smad 7 induces invasion, migration and in vivo metastasis in Non-Small Cell lung Cancer. Congress of the American Association of Cancer Research (AACR) Orlando, USA, April 2011
  104. Patil N, Rasheed SAK, Leupold J, Schwarzbach M, Allgayer H: A mechanistic study on the oncogenic role of FUS-CHOP fusion protein in liposarcoma. Congress of the American Association of Cancer Research (AACR) Orlando, USA, April 2011
  105. Mudduluru G, Körner A, Manegold C, Fulda S, Allgayer H: Enzastaurin stabilizes p53 and inhibits Axl gene expression and invasion in non-small cell lung cancer (NSCLC). Congress of the American Association of Cancer Research (AACR) Orlando, USA, April 2011
  106. Mudduluru G, Lunavat TR, Scharp M, Muppala S, Patil N, Abba M, Leupold JH, Allgayer H: miR-135b and miR-210 induce invasion, distant metastasis and EMT in colorectal cancer. 5th International EMT meeting in Biopolis, Singapore, 10-13 October 2011
  107. Mudduluru, G, Lunavat TR, Scharp M, Muppala S, Patil N, Leupold JH, Abba M, Allgayer H: miR-135b and miR-210 induce invasion and distant metastasis by targeting SIAH1 and SETD2 in colorectal cancer. Congress of the American Association of Cancer Research (AACR), Washington, USA, April 2012
  108. Rasheed SAK, Mudduluru G, Patil N, Leupold JH, Efferth T, Allgayer  H: Cetuximab and Artesunate synergistically inhibit the invasion and distant metastasis of non-small cell lung cancer. Congress of the American Association of Cancer Research (AACR), Washington, USA, April 2012
  109. Muppala S, Mudduluru G,  Leupold LH, Buergy D, Sleeman JP, Allgayer H:  CD24 induced miR-21 regulation is mainly mediated through Src, and both (CD24, Src) are post-transcriptionally downregulated by miR-34a. Congress of the American Association of Cancer Research (AACR), Washington, USA, April 2012

Kontextspalte